Kawaguchi Y
Department of Surgery, Kansai Medical University, Osaka, Japan.
Jpn J Surg. 1989 May;19(3):296-300. doi: 10.1007/BF02471405.
The concentration of abnormal prothrombin, or the protein induced by vitamin K absence or antagonist II (PIVKA-II) in 102 patients with hepatic disorders was measured by an enzyme immunoassay method. The concentration of PIVKA-II in the plasma was elevated in 11 out of 18 patients with hepatocellular carcinoma and also in a patient with hepatoblastoma. There was no correlation between serum alpha-fetoprotein and plasma PIVKA-II levels. The PIVKA-II level was normal in 11 patients who had metastatic carcinoma or cholangiocellular carcinoma. Moreover, benign diseases of the liver did not cause an elevation in PIVKA-II. PIVKA-II might be an useful marker of hepatocellular carcinoma because, like alpha-fetoprotein, its level changes in close relation to the effects of treatment.
采用酶免疫测定法检测了102例肝脏疾病患者异常凝血酶原或维生素K缺乏或拮抗剂II诱导蛋白（PIVKA-II）的浓度。18例肝细胞癌患者中有11例以及1例肝母细胞瘤患者血浆中PIVKA-II浓度升高。血清甲胎蛋白与血浆PIVKA-II水平之间无相关性。11例患有转移性癌或胆管细胞癌的患者PIVKA-II水平正常。此外，肝脏良性疾病不会导致PIVKA-II升高。PIVKA-II可能是肝细胞癌的一个有用标志物，因为与甲胎蛋白一样，其水平变化与治疗效果密切相关。
